Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential

  • Breast Cancer
Trial Status:

Completed

This trial runs in
Cities
  • Daytona Beach
Trial Identifier:

NCT02621957 GP29825

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This study is to assess the pharmacokinetics (PK) of a single dose of pravastatin with and without concomitant GDC-0810 administration in healthy female subjects of non-childbearing potential. During Period 1 (Day -1 to Day 4) PK parameters of pravastatin will be determined in the absence of GDC-0810. During Period 2 (Days 5-28) PK parameters of pravastatin will be determined in the presence of GDC-0810.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT02621957 , GP29825 Trial Identifier
      GDC-0810, Pravastatin Treatments
      Breast Cancer Condition
      Official Title

      A Phase 1, Open-Label Study to Evaluate the Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential

      Eligibility Criteria

      Female Gender
      ≥ 18 Years & ≤ 65 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria
      • Female subjects between 18 and 65 years of age, inclusive.
      • Female subjects of non-childbearing potential including non-pregnant, non-lactating, and either postmenopausal or surgically sterile for at least 45 days post procedure.
      • Within BMI range 18.5 to </= 29.9 kg/m^2, inclusive.
      • In good health, as determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory evaluations.
      • Receive an explanation of the mandatory pharmacogenomic (PgX) component of the study.
      Exclusion Criteria
      • Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder.
      • Previous history of adverse reaction to statins.
      • Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1) in Period 1.
      • Use of systemic hormone replacement therapy within 1 year prior to Check-in (Day -1).
      • History of use of tamoxifen, aromatase inhibitor or any other endocrine agent for treatment of breast cancer.
      • Female subject is pregnant lactating, or breast feeding.

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now